Panel Discussion | Mechanical Circulatory Support for High-Risk PCI and Shock

Tuesday, March 10, 2026

8:30 AM - 9:00 AM EST

Location: International Ballroom East

Moderator(s)

Mitchell Krucoff, MD, FACC, FAHA, FSCAI

Professor Medicine/Cardiology
Duke University Medical Center/Duke Clinical Research Institute
Durham, North Carolina, United States

Disclosure(s): Abbott Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Getinge: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Nipro Corporation: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Shockwave/Johnson&Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Terumo Corporation: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)
Robert W. Yeh, MD, MSc

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Disclosure(s): Abbott Vascular, Medtronic, Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); CathWorks: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Life Sciences: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Elixir Medical Corporation: Consulting Fees (e.g., advisory boards) (Ongoing)

Panel Discussant(s)

David Israeli, MD, MBA

CEO
Magenta Medical Ltd.
New York, New York, United States

Disclosure(s): Magenta Medical Ltd.: Employee (Ongoing), Stock Options [in privately held companies] (Ongoing)
Mauro Moscucci, MD, MBA, MPH

Medical Officer
Food and Drug Administration, Center for Devices and Radiological Health, Maryland, United States

Disclosure(s): No financial relationships to disclose
Jeffrey J. Popma, MD

Chief Scientific Officer
CRF
Newton, Massachusetts, United States

Disclosure(s): Medtronic: CMO ended Nov 2024 (Terminated, November 1, 2024), Stock-publicly held company (excluding mutual/index funds) (Terminated, November 1, 2024)

Disclosure(s):

Mitchell Krucoff, MD, FACC, FAHA, FSCAI: Abbott Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Getinge: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Nipro Corporation: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Shockwave/Johnson&Johnson: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Terumo Corporation: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)

Robert W. Yeh, MD, MSc: Abbott Vascular, Medtronic, Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); CathWorks: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Life Sciences: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Elixir Medical Corporation: Consulting Fees (e.g., advisory boards) (Ongoing)

David Israeli, MD, MBA: Magenta Medical Ltd.: Employee (Ongoing), Stock Options [in privately held companies] (Ongoing)

Mauro Moscucci, MD, MBA, MPH: No financial relationships to disclose

Jeffrey J. Popma, MD: Medtronic: CMO ended Nov 2024 (Terminated, November 1, 2024), Stock-publicly held company (excluding mutual/index funds) (Terminated, November 1, 2024)